Pharmacogenomics of platinum-based chemotherapy in NSCLC

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350(4):379-92
   PubMed Web of Science ®Google Scholar
• Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer–report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6(4):633-41
   PubMed Web of Science ®Google Scholar
• Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26(28):4617-25
   PubMed Web of Science ®Google Scholar
• Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478(1-2):23-43
   PubMed Web of Science ®Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33(1):9-23
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22(47):7265-79
   PubMed Web of Science ®Google Scholar
• Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines. 2nd Edition. Chest 2007;132(3 Suppl):1S-19S
   Google Scholar
• Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993;53(11):2581-6
   PubMed Web of Science ®Google Scholar
• Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002;99(22):14298-302
   PubMed Web of Science ®Google Scholar
• Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006;70(4):1390-4
   PubMed Web of Science ®Google Scholar
• Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3(12):1543-9
   PubMed Web of Science ®Google Scholar
• Komatsu M, Sumizawa T, Mutoh M, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000;60(5):1312-6
   PubMed Web of Science ®Google Scholar
• Nakayama K, Kanzaki A, Terada K, et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 2004;10(8):2804-11
   PubMed Web of Science ®Google Scholar
• Samimi G, Varki NM, Wilczynski S, et al. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003;9(16 Pt 1):5853-9
   PubMed Web of Science ®Google Scholar
• Liedert B, Materna V, Schadendorf D, et al. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003;121(1):172-6
   PubMed Web of Science ®Google Scholar
• Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007;110(1):138-47
   PubMed Web of Science ®Google Scholar
• Sohn JW, Lee SY, Lee SJ, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006;36(3):137-41
   PubMed Web of Science ®Google Scholar
• Wu X, Lu C, Ye Y, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008;18(11):955-65
   PubMed Web of Science ®Google Scholar
• Lai SL, Hwang J, Perng RP, Whang-Peng J. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncol Res 1995;7(1):31-8
   PubMed Web of Science ®Google Scholar
• Goto S, Iida T, Cho S, et al. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999;31(6):549-58
   PubMed Web of Science ®Google Scholar
• Moyer AM, Salavaggione OE, Wu TY, et al. Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res 2008;68(12):4791-801
   PubMed Web of Science ®Google Scholar
• Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008;7(10):3247-55
   PubMed Web of Science ®Google Scholar
• Lu C, Spitz MR, Zhao H, et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006;106(2):441-7
   PubMed Web of Science ®Google Scholar
• Booton R, Ward T, Heighway J, et al. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 2006;1(7):679-83
   PubMed Web of Science ®Google Scholar
• Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005;7(7):463-78
   PubMed Web of Science ®Google Scholar
• Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9(1):113-21
   PubMedGoogle Scholar
• Austin GE, Lam L, Zaki SR, et al. Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia 1993;7(9):1445-50
   PubMed Web of Science ®Google Scholar
• Piedrafita FJ, Molander RB, Vansant G, et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271(24):14412-20
   PubMed Web of Science ®Google Scholar
• Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 2007;39(7-8):1318-28
   PubMed Web of Science ®Google Scholar
• Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193(1-2):3-34
   PubMed Web of Science ®Google Scholar
• Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995;55(21):4760-4
   PubMed Web of Science ®Google Scholar
• Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer I 2002;94(14):1091-9
   PubMed Web of Science ®Google Scholar
• Lin J, Swan GE, Shields PG, et al. Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev 2007;16(10):2065-71
   PubMed Web of Science ®Google Scholar
• Matakidou A, el Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 2007;16(19):2333-40
   PubMed Web of Science ®Google Scholar
• Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003;4(4):237-41
   PubMedGoogle Scholar
• Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007;13(10):2876-81
   PubMed Web of Science ®Google Scholar
• Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15(8):1194-203
   PubMed Web of Science ®Google Scholar
• Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44(3):311-6
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14(6):1797-803
   PubMed Web of Science ®Google Scholar
• Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22(13):2594-601
   PubMed Web of Science ®Google Scholar
• Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 2006;106(11):2421-7
   PubMed Web of Science ®Google Scholar
• Mellon I, Hock T, Reid R, et al. Polymorphisms in the human xeroderma pigmentosum group A gene and their impact on cell survival and nucleotide excision repair. DNA Repair 2002;1(7):531-46
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao H, Wei Q, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 2003;24(3):505-9
   PubMed Web of Science ®Google Scholar
• Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009 [Epub ahead of print, doi: 10.1016/j.lungcan.2008.11.014]
   Google Scholar
• Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355(10):983-91
   PubMed Web of Science ®Google Scholar
• Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25(19):2747-54
   PubMed Web of Science ®Google Scholar
• Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10(15):4939-43
   PubMed Web of Science ®Google Scholar
• Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 2006;23(4):489-98
   PubMed Web of Science ®Google Scholar
• Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007;56(2):281-8
   PubMed Web of Science ®Google Scholar
• de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17(4):668-75
   PubMed Web of Science ®Google Scholar
• Betticher DC, Thatcher N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11(5):1005-11
   PubMed Web of Science ®Google Scholar
• Gautschi O, Hugli B, Ziegler A, et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006;51(3):303-11
   PubMed Web of Science ®Google Scholar
• Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25(19):2735-40
   PubMed Web of Science ®Google Scholar
• Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(10):1878-85
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356(8):800-8
   PubMed Web of Science ®Google Scholar
• Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005;47(2):183-92
   PubMed Web of Science ®Google Scholar
• Dumont P, Leu JI, Della Pietra AC 3rd, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33(3):357-65
   PubMed Web of Science ®Google Scholar
• Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19(2):1092-100
   PubMed Web of Science ®Google Scholar
• Han JY, Lee GK, Jang DH, et al. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113(4):799-807
   PubMed Web of Science ®Google Scholar
• Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004;64(12):4353-6
   PubMed Web of Science ®Google Scholar
• Shukla SJ, Duan S, Badner JA, et al. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 2008;18(3):253-62
   PubMed Web of Science ®Google Scholar
• Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007;81(3):427-37
   PubMed Web of Science ®Google Scholar
• Huang RS, Duan S, Kistner EO, et al. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 2008;7(9):3038-46
   PubMed Web of Science ®Google Scholar
• Shukla SJ, Duan S, Wu X, et al. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics 2009;3(2):128-42
   PubMedGoogle Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6(10):813-23
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Pommier Y. Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol 2003;326(10-11):909-20
   PubMed Web of Science ®Google Scholar
• Riedel RF, Porrello A, Pontzer E, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008;7(10):3141-9
   PubMed Web of Science ®Google Scholar
• Shen L, Kondo Y, Ahmed S, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 2007;67(23):11335-43
   PubMed Web of Science ®Google Scholar
• Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356(1):11-20
   PubMed Web of Science ®Google Scholar
• Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355(6):570-80
   PubMed Web of Science ®Google Scholar
• Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. P Natl Acad Sci USA 2006;103(15):5923-8
   PubMed Web of Science ®Google Scholar
• Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13(1):48-57
   PubMed Web of Science ®Google Scholar
• Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40(5):616-22
   PubMed Web of Science ®Google Scholar
• Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452(7187):633-7
   PubMed Web of Science ®Google Scholar
• Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452(7187):638-42
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 2008;359(8):789-99
   PubMed Web of Science ®Google Scholar
• Chen M, Kamat AM, Huang M, et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 2007;28(10):2160-5
   PubMed Web of Science ®Google Scholar
• Huang M, Dinney CP, Lin X, et al. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2007;16(1):84-91
   PubMed Web of Science ®Google Scholar
• Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78(3):464-79
   PubMed Web of Science ®Google Scholar
• Yang H, Lippman SM, Huang M, et al. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur J Cancer 2008;44(11):1603-11
   PubMed Web of Science ®Google Scholar
• Ye Y, Yang H, Grossman HB, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 2008;112(11):2467-74
   PubMed Web of Science ®Google Scholar
• Hildebrandt MA, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27(6):857-71
   PubMed Web of Science ®Google Scholar
• Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006;24(23):3789-98
   PubMed Web of Science ®Google Scholar
• Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11(4):1534-8
   PubMed Web of Science ®Google Scholar
• Etzel CJ, Kachroo S, Liu M, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res 2008;1(4):255-65
   PubMed Web of Science ®Google Scholar
• Spitz MR, Etzel CJ, Dong Q, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res 2008;1(4):250-4
   PubMed Web of Science ®Google Scholar
• Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99(9):715-26
   PubMed Web of Science ®Google Scholar
• Wu X, Lin J, Grossman HB, et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 2007;25(31):4974-81
   PubMed Web of Science ®Google Scholar